Peer-reviewedLicence not statedThe Journal of clinical psychiatry
GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Healthcare Utilization in Bipolar Disorder with Chronic Kidney Disease
- 1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
- 2Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
- 3Penn State College of Medicine, Hershey, PA, USA
Related
- Potential for GLP-1 Receptor Agonists in Irritable Bowel Syndrome
- Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
- GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study
- Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
BibTeX
@article{singh2026glp1,
title = {{GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Healthcare Utilization in Bipolar Disorder with Chronic Kidney Disease}},
author = {Balwinder Singh and Maria L Gonzalez Suarez and Hossam M Ali and Raman Baweja},
journal = {The Journal of clinical psychiatry},
year = {2026},
month = oct,
doi = {10.4088/jcp.26m16392},
url = {https://doi.org/10.4088/jcp.26m16392},
}
RIS
TY - JOUR
TI - GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Healthcare Utilization in Bipolar Disorder with Chronic Kidney Disease
AU - Balwinder Singh
AU - Maria L Gonzalez Suarez
AU - Hossam M Ali
AU - Raman Baweja
PY - 2026
DA - 2026/10/05
JO - The Journal of clinical psychiatry
DO - 10.4088/jcp.26m16392
UR - https://doi.org/10.4088/jcp.26m16392
SN - 0160-6689
SN - 1555-2101
ER -